Identification of novel extracellular signal-regulated kinase docking domain inhibitors.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2005-06-21

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM0501174PMID 15999996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phosphorylation regulates nucleophosmin targeting to the centrosome during mitosis as detected by cross-reactive phosphorylation-specific MKK1/MKK2 antibodies.

  2004cited by this paper
• MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors.

  2004cited by this paper
• Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.

  2004cited by this paper
• Targeting MAPK signalling: Prometheus' fire or Pandora's box?

  2004cited by this paper
• Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction.

  2004cited by this paper
• Requirement for phosphatidylinositol-3 kinase activity during progression through S-phase and entry into mitosis.

  2003cited by this paper
• Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

  2003cited by this paper
• Consideration of Molecular Weight during Compound Selection in Virtual Target-Based Database Screening

  2003cited by this paper
• The specificities of protein kinase inhibitors: an update.

  2003cited by this paper
• CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

  2003cited by this paper
• A Bipartite Mechanism for ERK2 Recognition by Its Cognate Regulators and Substrates*

  2003cited by this paper
• Ras-MAP Kinase Signaling Pathways and Control of Cell Proliferation: Relevance to Cancer Therapy

  2002cited by this paper
• BRAF and RAS mutations in human lung cancer and melanoma.

  2002cited by this paper
• Docking Sites on Substrate Proteins Direct Extracellular Signal-regulated Kinase to Phosphorylate Specific Residues*

  2001cited by this paper
• Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions

  2001cited by this paper
• Is There a Difference between Leads and Drugs? A Historical Perspective

  2001cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• Identification of a C-terminal Region That Regulates Mitogen-activated Protein Kinase Kinase-1 Cytoplasmic Localization and ERK Activation*

  2001cited by this paper
• Design of inhibitors of Ras--Raf interaction using a computational combinatorial algorithm.

  2001cited by this paper
• Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.

  2001cited by this paper
• Substrate Recognition Domains within Extracellular Signal-regulated Kinase Mediate Binding and Catalytic Activation of Mitogen-activated Protein Kinase Phosphatase-3*

  2000cited by this paper
• A conserved docking motif in MAP kinases common to substrates, activators and regulators

  2000cited by this paper
• Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

  2000cited by this paper
• MEK Wars, a new front in the battle against cancer

  1999cited by this paper
• The development and therapeutic potential of protein kinase inhibitors.

  1999cited by this paper
• Extracellular Signal-Regulated Kinase Activates Topoisomerase IIα through a Mechanism Independent of Phosphorylation

  1999cited by this paper
• Interaction of Mitogen-activated Protein Kinases with the Kinase Interaction Motif of the Tyrosine Phosphatase PTP-SL Provides Substrate Specificity and Retains ERK2 in the Cytoplasm*

  1999cited by this paper
• Signal transduction through MAP kinase cascades.

  1998cited by this paper
• Activation mechanism of the MAP kinase ERK2 by dual phosphorylation.

  1997cited by this paper
• Protein kinase cascades activated by stress and inflammatory cytokines

  1996cited by this paper
• A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1

  1996cited by this paper
• Activity of the MAP kinase ERK2 is controlled by a flexible surface loop.

  1995cited by this paper
• Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution

  1994cited by this paper
• Structure-Based Strategies for Drug Design and Discovery

  1992cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• A computational procedure for determining energetically favorable binding sites on biologically important macromolecules.

  1985cited by this paper
• Solvent-accessible surfaces of proteins and nucleic acids.

  1983cited by this paper
• A geometric approach to macromolecule-ligand interactions.

  1982cited by this paper

• Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death

  2024cites this paper
• Targeting a key protein-protein interaction surface on mitogen-activated protein kinases by a precision-guided warhead scaffold

  2024cites this paper
• First-in-Class Mitogen-Activated Protein Kinase p38α: MAPK-Activated Protein Kinase-2 (MK2) Dual Signal Modulator with Anti-inflammatory and Endothelial-stabilizing Properties.

  2024cites this paper
• Structure–Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review

  2024cites this paper
• The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance

  2024cites this paper
• Progress in the development of ERK1/2 inhibitors for treating cancer and other diseases.

  2024cites this paper
• Progress in the development of kinase inhibitors for treating asthma and COPD.

  2023cites this paper
• Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.

  2023cites this paper
• Navigating the ERK1/2 MAPK Cascade

  2023cites this paper
• Phosphorylation-Assisted Luciferase Complementation Assay Designed to Monitor Kinase Activity and Kinase-Domain-Mediated Protein–Protein Binding

  2023cites this paper
• Targeting mitochondrial metabolism for metastatic cancer therapy

  2022cites this paper
• The ERK2 DBP domain opposes pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm.

  2022cites this paper
• The Role of ERK1/2 Pathway in the Pathophysiology of Alzheimer’s Disease: An Overview and Update on New Developments

  2022cites this paper
• Targeted Inhibition of Select ERK1/2 Functions Mitigates Pathological Features of Asthma in Mice.

  2022cites this paper
• Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

  2022cites this paper
• Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study

  2021cites this paper
• RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation

  2021cites this paper
• Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy

  2020cites this paper
• Druggable exosites of the human kino-pocketome

  2020cites this paper
• Mechanistic analysis of an ERK2-interacting compound that inhibits mutant-BRAF expressing melanoma cells by inducing oxidative stress

  2020cites this paper
• A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition

  2020cites this paper
• Developing Kinase Inhibitors Using Computer-Aided Drug Design Approaches

  2020cites this paper
• Next Generation Kinase Inhibitors: Moving Beyond the ATP Binding/Catalytic Sites

  2020cites this paper
• Avoiding or Co-Opting ATP Inhibition: Overview of Type III, IV, V, and VI Kinase Inhibitors

  2020cites this paper
• Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations

  2020cites this paper
• Mechanistic Analysis of an Extracellular Signal–Regulated Kinase 2–Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress

  2020cites this paper
• Protein Kinase Interactions with Regulatory and Effector Proteins

  2020cites this paper
• Role of Angiopoietin-Like Protein 2 in Atrial Fibrosis Induced by Human Epicardial Adipose Tissue: Analysis Using Organo-Culture System.

  2020cites this paper
• A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.

  2019cites this paper
• Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial–Mesenchymal Transition in Cancer

  2019cites this paper
• Molecular Carcinogenesis

  2019cites this paper
• Effects of ATP‐competitive and function‐selective ERK inhibitors on airway smooth muscle cell proliferation

  2019cites this paper
• Computational approaches towards kinases as attractive targets for anticancer drug discovery and development.

  2018cites this paper
• Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.

  2018cites this paper
• Antidepressive effects of targeting ELK-1 signal transduction

  2018cites this paper
• ERK1/2 inhibitors: New weapons to inhibit the RAS‐regulated RAF‐MEK1/2‐ERK1/2 pathway

  2018cites this paper
• Natural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation

  2017cites this paper
• Novel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity

  2017cites this paper
• A high throughput assay to identify substrate‐selective inhibitors of the ERK protein kinases

  2017cites this paper
• Identification of Potential Small Molecule Binding Pockets in p38α MAP Kinase

  2017cites this paper
• Anti-Inflammatory Activity Endothelial-Stabilizing and-Specific MAPK Inhibitors with α Novel Noncatalytic Substrate-Selective p 38

  2017influential citation
• The Search for Herbal Antibiotics: An In-Silico Investigation of Antibacterial Phytochemicals

  2016cites this paper
• Alphavirus protease inhibitors from natural sources: A homology modeling and molecular docking investigation

  2016cites this paper
• Enzymatic Studies in Medicinal Chemistry of Neglected Diseases.

  2016cites this paper
• Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma

  2016cites this paper
• Bisphenol A Induces Migration through a GPER-, FAK-, Src-, and ERK2-Dependent Pathway in MDA-MB-231 Breast Cancer Cells.

  2016cites this paper
• The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.

  2015cites this paper
• Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain

  2015cites this paper
• Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf.

  2015cites this paper
• MEK‐independent ERK activation in human neutrophils and its impact on functional responses

  2015cites this paper
• Investigating Novel Biological Mechanisms of Head and Neck Cancers

  2014cites this paper
• Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.

  2014cites this paper
• VEGF signal system: the application of antiangiogenesis.

  2014cites this paper
• Structural Modifications of (Z)-3-(2-aminoethyl)-5-(4- ethoxybenzylidene)thiazolidine-2,4-dione that Improve Selectivity for the Inhibition of Melanoma Cells Containing Active ERK Signaling

  2014cites this paper
• MicroRNA-193b Enhances Tumor Progression via Down Regulation of Neurofibromin 1

  2013cites this paper
• A Fluorescence‐Based Assay for p38α Recruitment Site Binders: Identification of Rooperol as a Novel p38α Kinase Inhibitor

  2013cites this paper
• Supporting cells and ERK signalling: determining their roles in hair cell death

  2013cites this paper
• Benzo-[a]-pyrene induces FAK activation and cell migration in MDA-MB-231 breast cancer cells

  2013cites this paper
• Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling.

  2013cites this paper
• Approaches to discover non-ATP site kinase inhibitors

  2013cites this paper
• Epitope guided engineering of monobody binders for in vivo inhibition of Erk‐2 signaling

  2013cites this paper
• Domain-Based Biosensor Assay to Screen for Epidermal Growth Factor Receptor Modulators in Live Cells

  2012cites this paper
• Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases.

  2012cites this paper
• Angiogenesis , Metastasis , and the Cellular Microenvironment Constitutive KRas G 12 D Activation of ERK 2 Speci fi cally Regulates 3 D Invasion of Human Pancreatic Cancer Cells via MMP-1

  2012cites this paper
• Regulation of RUNX2 transcription factor–DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity

  2012cites this paper
• ERK1/2 MAP kinases: structure, function, and regulation.

  2012cites this paper
• RK 1 / 2 MAP kinases : Structure , function , and regulation

  2012cites this paper
• Overactivation of Ras signaling pathway in CD133+ MPNST cells

  2012cites this paper
• PRAS40 Is an Integral Regulatory Component of Erythropoietin mTOR Signaling and Cytoprotection

  2012cites this paper
• Regulation and inhibition of MAP kinases

  2012cites this paper
• Prospects of Modulating Protein–Protein Interactions

  2012cites this paper
• Modulators of protein-protein interactions: novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules.

  2011cites this paper
• Insulin receptor signaling activated by penta-O-galloyl-α-d-glucopyranose induces p53 and apoptosis in cancer cells

  2011cites this paper
• Activation of ERK 2 Specifically Regulates 3 D Invasion of Human Pancreatic Cancer Cells via MMP-1

  2011cites this paper
• Small‐Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics

  2011cites this paper
• Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9

  2011influential citation
• Constitutive K-RasG12D Activation of ERK2 Specifically Regulates 3D Invasion of Human Pancreatic Cancer Cells via MMP-1

  2011cites this paper
• Development of Dual-Pathway Inhibitors of Raf/MEK/ERK and PI3K/Akt Signaling Pathways.

  2011cites this paper
• Preclinical Models for Anticancer Drug Development

  2011cites this paper
• Cafestol, a coffee-specific diterpene, is a novel extracellular signal-regulated kinase inhibitor with AP-1-targeted inhibition of prostaglandin E2 production in lipopolysaccharide-activated macrophages.

  2010cites this paper
• Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.

  2010cites this paper
• Update 1 of: Beta-strand mimetics.

  2010cites this paper
• A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.

  2010cites this paper
• Biased retrieval of chemical series in receptor-based virtual screening

  2010cites this paper
• Use of inhibitors in the study of MAP kinases.

  2010cites this paper
• Chemical space sampling by different scoring functions and crystal structures

  2010cites this paper
• Drug Design: Docking: a domesday report

  2010cites this paper
• Targeting the translational machinery as a novel treatment strategy for hematologic malignancies.

  2010cites this paper
• Activation of mitogen-activated protein kinases cellular signal transduction pathway in mammalian cells induced by silicon carbide nanowires.

  2010cites this paper
• Choroidal endothelial cell activation in age-related macular degeneration

  2010cites this paper
• Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

  2009cites this paper
• Protein-protein interaction inhibition (2P2I): fewer and fewer undruggable targets.

  2009cites this paper
• Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.

  2009cites this paper
• Development of extracellular signal-regulated kinase inhibitors.

  2009cites this paper
• The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions.

  2009cites this paper
• Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.

  2009cites this paper
• ERK 1/2 AND p38 MAPK PATHWAYS ARE BOTH INVOVLED IN THE EXPRESSION OF INTERLEUKIN-6, -8, AND CYCLOOXYGENASE-2 IN THROMBOCYTES STIMULATED WITH LIPOPOLYSACCHARIDE

  2009cites this paper
• Untersuchung von p38α MAP-Kinase/Inhibitor-Komplexen in Lösung mittels Kernresonanzspektroskopie

  2008influential citation
• Mitogen‐activated Protein Kinases (MAPKs): ERKs, JNKs, and p38s

  2008cites this paper
• ERK inhibitors as a potential new therapy for rheumatoid arthritis.

  2008cites this paper